3 Maternity and Critical Care Hospital Operator, Multi-Specialty Hospital Network and Tertiary Care Campus Operator Stocks With a Strong Future Roadmap: Jupiter Life Line Hospitals, Fortis Healthcare and Global Health

Hospital chain stocks with bed additions give investors a way to track businesses that sit close to everyday demand in India. Jupiter Life Line Hospitals, Fortis Healthcare and Global Health cover a maternity and critical care hospital operator, a multi-specialty hospital network and a tertiary care campus operator.

This list covers three hospital chain stocks with bed additions with complete current figures: Jupiter Life Line Hospitals, Fortis Healthcare and Global Health. Every figure comes from the latest reported financials and the 26 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Hospital Chain Stocks with Bed Additions?

Hospital chain stocks with bed additions are listed healthcare companies that run hospitals in large and mid-sized cities. Their earnings depend on bed capacity, patient volumes, specialty mix and pricing.

Hospital Chain Stocks with Bed Additions at a Glance

On valuation, Jupiter Life Line Hospitals and Fortis Healthcare trade at a P/E below the industry P/E, while Global Health trades above it, which reflects the growth the market already expects. Readers comparing hospital chain stocks with bed additions should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Hospital Chain Stocks with Bed Additions Have a Strong Roadmap in India?

Hospital chain stocks with bed additions have a strong roadmap in India because rising insurance cover, medical travel and demand for advanced treatment keep lifting admissions at organised hospital chains.

• Bed additions. New capacity adds patient volumes.
• Specialty care. Advanced treatments raise revenue per patient.
• Insurance cover. More households can afford private care.

Why Jupiter Life Line Hospitals Features Among These Hospital Chain Stocks with Bed Additions

Among the hospital chain stocks with bed additions on this list, Jupiter Life Line Hospitals runs multi-speciality hospitals in Pune, Thane and Indore, with strong services in maternity, child care, critical care and advanced surgery.

Revenue rose from Rs 737 crore in FY22 to Rs 1,542 crore in FY26, a compound annual growth rate of 20.3%. Net profit grew from Rs 51.1 crore in FY22 to Rs 194 crore in FY26, which works out to a compound annual growth rate of 39.6%.

The company has a return on equity of 11.4%, a debt to equity ratio of 0.41 and a market capitalisation of Rs 8,007 crore. The stock trades at a P/E of 42.6, below the industry P/E of 58.4.

Roadmap: The company is adding beds and expanding to new locations while growing specialist services. Rising demand for quality private care in its cities supports occupancy.

What to watch: Follow bed additions, occupancy levels and revenue per occupied bed.

Why Fortis Healthcare Features Among These Hospital Chain Stocks with Bed Additions

Among the Pune and Gurugram hospital shares on this list, Fortis Healthcare operates a network of multi-specialty hospitals across India, with strengths in cardiac sciences, oncology, neurosciences and orthopaedics, and it also runs a diagnostics business.

The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6.

Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore.

Roadmap: The company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

What to watch: Track bed additions, occupancy and revenue per occupied bed.

Why Global Health Features Among These Hospital Chain Stocks with Bed Additions

Among the three companies on this list, Global Health, which operates the Medanta brand, runs tertiary-care hospitals led by its flagship campus in Gurugram, along with facilities in Lucknow, Patna, Ranchi, Indore and Noida.

Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%.

In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6.

Roadmap: Management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

What to watch: Watch the ramp-up speed of newer hospitals and the pace of doctor additions at each site.

Jupiter Life Line Hospitals vs Fortis Healthcare vs Global Health on Key Financials

The table below sets the three hospital chain stocks with bed additions side by side on revenue, profit and margin, using reported figures.

Global Health posts the highest return on equity in this group at 14.1%. Fortis Healthcare has the largest FY26 revenue at Rs 9,178 crore, and Jupiter Life Line Hospitals shows the fastest revenue growth with a 20.3% compound annual rate. A useful habit with hospital chain stocks with bed additions is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Hospital Chain Stocks with Bed Additions

Every theme carries risks that deserve a check before any decision. For these hospital chain stocks with bed additions, the main points are: Long-term Pune and Gurugram hospital shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Capacity timing. New beds take time to mature.
• Pricing. Health care pricing rules can affect revenue.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter hospital chain stocks with bed additions by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Hospital Chain Stocks with Bed Additions

Hospital chain stocks with bed additions work best when investors track growth, valuation and return on equity side by side. Jupiter Life Line Hospitals, Fortis Healthcare and Global Health each have a clear plan to expand. Based on the 26 October 2026 close, Jupiter Life Line Hospitals trades at Rs 252.95, Fortis Healthcare at Rs 734.7 and Global Health at Rs 1,212.

Download the Univest iOS App or Univest Android App to track hospital chain stocks with bed additions, set price alerts and get research-backed stock ideas.

What are hospital chain stocks with bed additions?

Ans. Hospital chain stocks with bed additions are listed healthcare companies that run hospitals in large and mid-sized cities. Their earnings depend on bed capacity, patient volumes, specialty mix and pricing. This list looks at three of them, Jupiter Life Line Hospitals, Fortis Healthcare and Global Health, using reported FY22 to FY26 financials and the 26 October 2026 closing prices.

Which hospital chain stocks with bed additions are covered in this list?

Ans. This list covers Jupiter Life Line Hospitals, Fortis Healthcare and Global Health. Based on the 26 October 2026 close, Jupiter Life Line Hospitals traded at Rs 252.95, Fortis Healthcare at Rs 734.7 and Global Health at Rs 1,212. Their return on equity ranges from 10.5% to 14.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 20.3%.

Why do hospital chain stocks with bed additions have a strong future roadmap in India?

Ans. Hospital chain stocks with bed additions have a strong roadmap in India because rising insurance cover, medical travel and demand for advanced treatment keep lifting admissions at organised hospital chains. The main drivers are as follows. Bed additions. New capacity adds patient volumes. Specialty care. Advanced treatments raise revenue per patient. Insurance cover. More households can afford private care. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Jupiter Life Line Hospitals performed financially?

Ans. Revenue rose from Rs 737 crore in FY22 to Rs 1,542 crore in FY26, a compound annual growth rate of 20.3%. Net profit grew from Rs 51.1 crore in FY22 to Rs 194 crore in FY26, which works out to a compound annual growth rate of 39.6%. The company has a return on equity of 11.4%, a debt to equity ratio of 0.41 and a market capitalisation of Rs 8,007 crore. The stock trades at a P/E of 42.6, below the industry P/E of 58.4. Looking ahead, the company is adding beds and expanding to new locations while growing specialist services. Rising demand for quality private care in its cities supports occupancy.

How has Fortis Healthcare performed financially?

Ans. Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

How has Global Health performed financially?

Ans. Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P/E of 60.3, above the industry P/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.

What risks should investors check before buying hospital chain stocks with bed additions?

Ans. Investors should check a few risks before buying hospital chain stocks with bed additions. Capacity timing. New beds take time to mature. Pricing. Health care pricing rules can affect revenue. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of hospital chain stocks with bed additions investment advice?

Ans. No. This article is educational and uses publicly available data as of the 26 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.